Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profile at single cell level in prostate cancer PDX, LucaP 70CR treated with Bromo- and -extraterminal domain (BET) inhibitor Pelabresib and vehicle control

ABSTRACT: Gene expression profile at single cell level in prostate cancer PDX, LucaP 70CR treated with Bromo- and -extraterminal domain (BET) inhibitor Pelabresib and vehicle control

PROVIDER: PRJNA1067151 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27668400.fastq.gz	Fastqsanger.gz
	SRR27668401.fastq.gz	Fastqsanger.gz
	SRR27668402.fastq.gz	Fastqsanger.gz
	SRR27668403.fastq.gz	Fastqsanger.gz
	SRR27668404.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 35CR

Project description:To study the effect of inhibiting AR and HNF1A/HNF4G activity either alone or in combination on the growth of CRPC PDX LuCaP 35CR

2025-01-18 | GSE254665 | GEO

BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 77CR

Project description:To study the effect of inhibiting AR and HNF1A/HNF4G activity either alone or in combination on the growth of CRPC PDX LuCaP 77CR.

2025-01-18 | GSE253805 | GEO

Gene expression profile at single cell level in prostate cancer PDX, LucaP 70CR treated with Bromo- and -extraterminal domain (BET) inhibitor Pelabresib and vehicle control

Project description:We used single-cell RNA-sequencing to evaluate the effect of BET inhibitor, pelabresib on AR and HNF1A/HNF4G regulated transcriptome in prostate cancer PDX

2025-01-18 | GSE253806 | GEO

mCRPC LuCaP PDXs ChIP-seq

Project description:Informed consent was obtained to collect human mCRPC tissues and generate the patient-derived xenograft tumors as described previously (Labrecque et al., 2019; Nguyen et al., 2017). The study was approved by the University of Washington Human Subjects Division institutional review board (no. 39053). All animal studies were approved by University of Washington IACUC and performed according to NIH guidelines. Molecular characterization of AR+ mCRPC LuCaP PDXs 70CR, 78CR, 81CR, 96CR, 105CR, 136CR and 147CR was previously described (Labrecque et al., 2019; Nguyen et al., 2017). LuCaP PDX 167CR was established from a liver metastasis of 77-year-old Caucasian male who died of abiraterone-, carboplatin- and docetaxel-resistant CRPC. LuCaP 167CR expresses AR, responds to castration and is negative for synaptophysin. PDX cellular morphology recapitulates the original liver metastasis (Supplementary Figure S8A).

2022-04-06 | GSE163220 | GEO

BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 77CR

Project description:BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 77CR

| PRJNA1067152 | ENA

BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 35CR

Project description:BET inhibitor Pelabresib and AR inhibitor enzalutamide perturbed pathways in prostate cancer CRPC PDX LuCaP 35CR

| PRJNA1071482 | ENA

RNA seq analysis of LuCaP Prostate Cancer Patient-Derived Xenografts

Project description:We assembled a prostate xenograft interactome from a large data set with 128 RNA sequencing expression profiles generated through administration of 13 small molecule perturbagens in vivo to 5 distinct and genetically diverse LuCaP xenograft lines (LuCaP 73, LuCaP77, LuCaP 78, LuCaP 81, LuCaP 147), with half of the xenograft samples collected from hosts castrated for 1 week.

2023-01-23 | GSE184427 | GEO

single-cell RNA-seq analysis for high-dose testosterone treated LuCaP 96CR PDX tumors

Project description:single-cell RNA-seq analysis for high-dose testosterone treated LuCaP 96CR PDX tumors

| PRJNA1148986 | ENA

Bromodomain targeting overcomes treatment resistance in distinct molecular subtypes of melanoma

Project description:NSG mice bearing tumors from the MM-300 PDX line were treated with vehicle or the combination of bromosporine + cobimetinib (bromo+cobi)

2022-07-01 | GSE169656 | GEO

Inhibition of ERG Activity in Patient Derived Prostate Cancer Xenografts using the Small Molecule Inhibitor YK-4-279

Project description:ERG activity was blocked using YK-4-279 in three subcutaneously implanted ERG+ (LuCaP 23.1, 86.2, and 35) and one ERG- (LuCaP 96) PDX. Tumor volume (TV), body weight (BW), serum prostate specific antigen (PSA), and overall survival (OS) were compared to vehicle treated controls. Changes in gene expression were assessed by RNASeq and tissue microarrays were constructed to assess necrosis, proliferation, apoptosis, microvessel density, and ERG expression.

2017-11-16 | GSE86387 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data